Samyang

Samyang Corporation, Expansion of global market by launching two new industrial water treatment equipment

Retrieved on: 
Monday, December 11, 2023
Water quality, Reverse osmosis, EDI, Samyang, Multimedia, Triangle, Power plant engineering, Seawater, Semiconductor, Ion exchange, Pollution, Water, Growth, Electricity, Power, Chromatography, Phosphorus, Bottled water, Lithium, Electrodeionization

Samyang Corporation (CEO Kang Ho-Sung) announced that they have released new products with their industrial water treatment brand name, "TRILITE" which are TRILITE RO, Reverse Osmosis, and TRILITE EDI, Electrodeionizer.

Key Points: 
  • Samyang Corporation (CEO Kang Ho-Sung) announced that they have released new products with their industrial water treatment brand name, "TRILITE" which are TRILITE RO, Reverse Osmosis, and TRILITE EDI, Electrodeionizer.
  • It is a product specifically designed for brackish water, which contains less salt than seawater and is specialized in the manufacture of industrial water.
  • Samyang Corporation, along with ion exchange resin, has established a core water treatment materials line-up for ultrapure water production by launching its RO membrane and EDI.
  • He added, "With differentiated technology and a brand, "TRILITE" that can provide comprehensive solutions, Samyang Corporation will become a leading company in the global water treatment market."

Samyang Corporation, Expansion of global market by launching two new industrial water treatment equipment

Retrieved on: 
Monday, December 11, 2023
Water quality, Reverse osmosis, EDI, Samyang, Triangle, Power plant engineering, Seawater, Semiconductor, Ion exchange, Pollution, Water, Growth, Electricity, Power, Chromatography, Phosphorus, Bottled water, Lithium, Electrodeionization

Samyang Corporation (CEO Kang Ho-Sung) announced that they have released new products with their industrial water treatment brand name, "TRILITE" which are TRILITE RO, Reverse Osmosis, and TRILITE EDI, Electrodeionizer.

Key Points: 
  • Samyang Corporation (CEO Kang Ho-Sung) announced that they have released new products with their industrial water treatment brand name, "TRILITE" which are TRILITE RO, Reverse Osmosis, and TRILITE EDI, Electrodeionizer.
  • It is a product specifically designed for brackish water, which contains less salt than seawater and is specialized in the manufacture of industrial water.
  • Samyang Corporation, along with ion exchange resin, has established a core water treatment materials line-up for ultrapure water production by launching its RO membrane and EDI.
  • He added, "With differentiated technology and a brand, "TRILITE" that can provide comprehensive solutions, Samyang Corporation will become a leading company in the global water treatment market."

Samyang Signs Partnership Agreement with Yxintent, China for Dermal Filler Lafullen®

Retrieved on: 
Wednesday, June 7, 2023
KRW, Partnership, Lead, Multimedia, PCL, Science Citation Index Expanded, SCI, Safety, Samyang, Pharmaceutical industry

Samyang Holdings signed a partnership agreement with Hangzhou Yxintent, a Chinese medical devices and aesthetics specialist company for the export of Lafullen® at Samyang Discovery Center in Pangyo.

Key Points: 
  • Samyang Holdings signed a partnership agreement with Hangzhou Yxintent, a Chinese medical devices and aesthetics specialist company for the export of Lafullen® at Samyang Discovery Center in Pangyo.
  • Through this contract, Yxintent will conduct clinical trials and obtain approval for Lafullen® in China, and once approved, will exclusively sell Lafullen® in China.
  • Being the first Korean company entering the China's biodegradable polymer dermal filler market, Samyang Holdings plans to supply about KRW 100 billion worth of finished products over the next five years.
  • With this export agreement with Yxintent, Samyang Holdings plans to take the lead in China's rapidly growing polymer filler market.

Samyang Holdings Enters Partnership with LG Chem for the Development of Innovative Cancer Therapeutics

Retrieved on: 
Thursday, April 20, 2023
Cancer, Partnership, Protein, LG Chem, Therapy, Patient, Messenger, Samyang, Pharmaceutical industry, Vaccine

SEOUL, South Korea, April 20, 2023 /PRNewswire/ -- Samyang Holdings and LG Chem have announced their recent execution of strategic partnership agreement on Thursday, April 20th, for development of novel mRNA-based cancer therapeutics that utilizes Samyang's proprietary drug delivery technology.

Key Points: 
  • SEOUL, South Korea, April 20, 2023 /PRNewswire/ -- Samyang Holdings and LG Chem have announced their recent execution of strategic partnership agreement on Thursday, April 20th, for development of novel mRNA-based cancer therapeutics that utilizes Samyang's proprietary drug delivery technology.
  • Under the terms of the agreement, Samyang Holdings grants non-exclusive rights to "NanoReady" technology and is responsible for supplying its key components to LG Chem, and LG Chem will be implementing "NanoReady" technology to develop innovative mRNA-based cancer therapeutics with maximal therapeutic effects.
  • "LG Chem has exceptional R&D expertise in innovative drug development and a number of promising new drug pipelines," said Young-Joon Lee., CEO, Samyang Holdings Biopharm Division, "Taking this recent deal as a driving force, we will continue to strengthen our partnership with LG Chem.
  • By leveraging the capabilities of the two companies, we hope to accelerate the development of innovative cancer therapy to significantly improve the lives of suffering cancer patients."

BRANDSTARS Announces ‘2022 Korean Wave Brands (KWB)’

Retrieved on: 
Monday, December 12, 2022
Technology, Mobile, Wireless, Cosmetics, Retail, Entertainment, EV, Electric Vehicles, Destinations, Travel, Automotive, Department Stores, Music, Food, Beverage, Consumer Electronics, Fashion, LG, OLED TV, LG Household & Health Care, Samsung, KWB, Samsung Galaxy Z series, Samsung Medical Center, BTS, Gentle Monster, Samyang, ISSAC, WHOO, Korean wave, TROMM, Lotte Department Store, Tourism, Health, CJ, Cosmetics

The representative brands for each category of 2022 Korean Wave Brands (KWB) hosted by the BRANDSTARS Selection Committee have been announced.

Key Points: 
  • The representative brands for each category of 2022 Korean Wave Brands (KWB) hosted by the BRANDSTARS Selection Committee have been announced.
  • Marking the fifth anniversary this year, this event to select and announce the representative Korean Wave brands concurrently through major media outlets in China and Southeast Asia is aimed at helping consumers make better choices by providing accurate information to overseas consumers.
  • As the brands representing each industry, Samsung Electronics Samsung Galaxy Z Fold4 and Z Flip4 , Hyundai Motor Companys IONIQ5 , LG Electronics OLED TV and TROMM , Dong-A Pharms Bacchus were selected.
  • Sinjeon Tteok-bokki and Samyang Foods Buldak Hot Chicken Flavor Ramen were also selected as the brands representing spicy flavors.

Samyang Foods’ Buldak Hot Chicken Flavor Ramen to Sponsor 2022 MAMA AWARDS

Retrieved on: 
Tuesday, November 29, 2022
Music, Food, Beverage, Retail, Events, Concerts, Entertainment, Samyang Food, Food, Kyocera Dome Osaka, VCR, Multimedia, MAMA, KRX, Samyang, Hot Chicken Flavor Ramen, Music, Baking, Nightclub

Samyang Foods (KRX: 003230) announced on 29th of November that it will sponsor 2022 MAMA AWARDS to mark the 10th anniversary of its launch of Buldak Hot Chicken Flavor Ramen.

Key Points: 
  • Samyang Foods (KRX: 003230) announced on 29th of November that it will sponsor 2022 MAMA AWARDS to mark the 10th anniversary of its launch of Buldak Hot Chicken Flavor Ramen.
  • View the full release here: https://www.businesswire.com/news/home/20221128005855/en/
    Samyang Foods sponsors 2022 MAMA AWARDS to celebrate 10th anniversary of Buldak Hot Chicken Flavor Ramen (Graphic: Business Wire)
    Started in 1999 as the Mnet Video Music Festival, Mnet Asian Music Awards (MAMA AWARDS) grew into an Asian-level music awards ceremony for the first time in Korea in 2009, establishing itself as the best music awards ceremony in Korea.
  • A Samyang Foods official said, Samyang Foods has sponsored numerous global events in the Americas and Europe throughout this year to commemorate the 10th anniversary of its launch of Hot Chicken Flavor Ramen.
  • He added, We will show the potential of Samyang Foods Hot Chicken Flavor Ramen to the world by launching localized flavors for each country.

Samyang enters full-scale mass production of eco-friendly additive-free transparent flame-retardant polycarbonate (T-FR PC)

Retrieved on: 
Wednesday, July 20, 2022
Laboratory, Food, Electronics, UL, Building material, Safety, Multimedia, Lighting, Car, Eco-friendly dentistry, Technology, Samyang, Organobromine compound, UL (safety organization), Bromine, Chlorine, Thermoplastic

Polycarbonate is a transparent, impact- and heat-resistant engineering plastic material often used for the interior and exterior finishes of vehicles, electronic appliances, soundproof walls, and medical device components.

Key Points: 
  • Polycarbonate is a transparent, impact- and heat-resistant engineering plastic material often used for the interior and exterior finishes of vehicles, electronic appliances, soundproof walls, and medical device components.
  • Samyang Corporation (President: Kang Ho-sung), a Samyang Group affiliate specializing in chemicals and food, announced on the 20th that it has developed a transparent flame-retardant polycarbonate material with no flame retardant agent using its own in-house technology and established the system for full-scale mass production.
  • Its eco-friendly T-FR PC will be manufactured at the Samyang Corporation's Engineered Plastic Plant and Samyang Kasei Plant in Jeonju.
  • While a flame-retardant agent is often added in the manufacturing of transparent flame-retardant polycarbonate, the use of such an agent reduces the material's main advantages of transparency and impact-resistance.

The MDS Foundation Celebrates MDS World Awareness Day With Their 4th Annual Move for MDS 5k Walk at Boston Common and Virtually Around the World

Retrieved on: 
Wednesday, October 20, 2021
Lymphatic system, Family, Twitter, China National Gold Group Corporation, Instagram, GLOBE, Patient, MDS, Samyang, Novartis, Boston Common, National, Organization, Engagement, Survival rate, Movement, Awareness, Takeda Oncology, Disease, Pacific Northwest, Region, Myelodysplastic syndrome, Cancer, Motivation, Nursing, Caregiver, Diagnosis, AbbVie, Research, Silence Therapeutics, Pharmaceutical industry

Great strides have been made in advancing innovative research andtreatments for MDS, but like other rare diseases, more awareness andsupport are needed.

Key Points: 
  • Great strides have been made in advancing innovative research andtreatments for MDS, but like other rare diseases, more awareness andsupport are needed.
  • "This is the fourth year we are partnering with our communities to Move forMDS," said Dr. Stephen Nimer, chairman of the MDS Foundation.
  • The Move for MDS program is made possible by the support of incredibleorganizations committed to the MDS community.
  • Now in itsfourth year, the Move for MDS walk, held on the eve of MDS WorldAwareness Day, brings together a global community to raise awareness forthis rare cancer.

Samyang Biopharm USA, Inc. and Spanish National Research Council (CSIC) Announce Strategic Collaboration to Study SYB-010; A First-in-Class, Immune Stimulatory Monoclonal Antibody

Retrieved on: 
Monday, August 30, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Collaboration, LLC, Metastasis, Samyang, European Research Area, Therapy, Spanish National Research Council, Life, European, CISC, Survival, CSIC, Innovation, Ligand, Antibody, Ministry of Science and Innovation (New Zealand), Reyburn, DRS, Biology, NK, Ministry, Â, Patient, General Electric Research Laboratory, Organization, NKG2D, Material, ERA, Fine chemical, Pharmaceutical industry, the Spanish National Research Council, Samyang Biopharm USA, Inc., THE SPANISH NATIONAL RESEARCH COUNCIL, SAMYANG BIOPHARM USA, INC.

Samyang Biopharm USA, Inc. ( https://us.samyangbiopharm.com ) a subsidiary of Samyang Holdings Corp. ( https://samyangbiopharm.com/eng ), announced today that the company has entered into a research collaboration with the Spanish National Research Council (CSIC), a state agency for scientific research and technological development.

Key Points: 
  • Samyang Biopharm USA, Inc. ( https://us.samyangbiopharm.com ) a subsidiary of Samyang Holdings Corp. ( https://samyangbiopharm.com/eng ), announced today that the company has entered into a research collaboration with the Spanish National Research Council (CSIC), a state agency for scientific research and technological development.
  • We look forward to future involvement within this collaboration" said Sean McKenna, Ph.D., Vice President of Research, Samyang Biopharm USA.
  • SYB-010 is a monoclonal antibody targeting the human NKG2D-ligands, MCA/B, which has shown a clear immumodulatory effect in pre-clinical models.
  • The Spanish National Research Council is a state agency for scientific research and technological development.

Samyang Biopharm USA and Dr. Hyun-Sung Lee, Baylor College of Medicine Announce Strategic Collaboration to Study the Effects of SYB-010 On Overcoming Resistance to Immune Checkpoint Therapy

Retrieved on: 
Monday, August 23, 2021
Research, Biotechnology, Health, University, Pharmaceutical, Other Science, Science, Education, Oncology, LLC, Samyang, Investor, Baylor College of Medicine, PD-1, Cancer, Clinical and Translational Science Award, Program, Therapy, PD-L1, MHC, Research, Drug discovery, System, Assistant, SMIC, Business development, NK, MBA, Baylor University, Patient, Partnership, Investigational New Drug, CEO, Doctor of Philosophy, Systems biology, Pharmaceutical industry

Samyang is constantly looking for novel drug discovery platforms with the potential to transform drug development to address the unmet needs of patients.

Key Points: 
  • Samyang is constantly looking for novel drug discovery platforms with the potential to transform drug development to address the unmet needs of patients.
  • This strategic collaboration is a significant step in meeting that goal.
  • SYB-010 (formerly CuraB-10), is a first-in-class therapeutic acquired by Samyang Biopharm USA from CanCure, LLC, in 2019.
  • In cancer model systems, SYB-010 potently activates both the T lymphocyte and NK (natural killer) cell arms of the anti-tumor immune response.